Caristo Diagnostics has developed the CaRi-Heart® technology, which represents a significant advancement in the detection and management of coronary artery disease (CAD) by focusing on coronary inflammation. This innovative approach utilizes artificial intelligence (AI) to analyze routine coronary computed tomography angiography (CCTA) scans, allowing for the visualization and quantification of inflammation in the coronary arteries. The CaRi-Heart FAI-Score™ is the first commercially available tool that can detect and measure this inflammation, providing clinicians with critical information to assess heart attack risk and tailor treatment strategies effectively. The technology has received marketing authorization in the UK, Europe, and Australia, and is now integrated into front-line cardiac care in various hospitals and clinics.

Recent studies, including a landmark publication in The Lancet, have demonstrated the predictive power of the CaRi-Heart technology in identifying patients at risk for cardiac events, even in those without obstructive CAD. The findings indicate that coronary inflammation, as measured by the FAI-Score, can predict fatal and non-fatal cardiac events independently of traditional risk factors and imaging interpretations. This capability positions CaRi-Heart as a transformative tool in preventive cardiology, shifting the focus from merely identifying existing disease to proactively managing and preventing future cardiac events. The ongoing ORFAN registry, which aims to include data from 250,000 patients, further underscores the potential of this technology to revolutionize cardiac care by identifying high-risk patients who may otherwise appear to have normal CCTA results.

United Kingdom

Caristo Diagnostics has been formed to bring revolutionary cardiovascular diagnostic tools to patients worldwide. Our proprietary technology transforms the accuracy of routine cardiac CT scans by extracting new information that is otherwise invisible, greatly enhancing the power to predict cardiovascular risk and refine treatment decisions.

Our Website: https://www.caristo.com

Follow us on Twitter: https://twitter.com/CaristoHeart

Caristo Diagnostics

Company Details